丹参川芎嗪注射液联合脑心通治疗冠心病心绞痛临床分析

Clinical Analysis of Salvia Miltiorrhiza and Ligustrazine Injection Combined Naoxintong in the Treatment of Angina Pectoris

目的:探讨丹参川芎嗪注射液联合脑心通治疗冠心病心绞痛的临床疗效。方法:冠心病心绞痛患者112例,采用随机数字表法随机分为治疗组和对照组,各56例。对照组采用丹参川芎嗪注射液静脉滴注治疗,治疗组在此基础上口服脑心通治疗,15d为1个疗程。观察2组患者治疗前后的心绞痛症状、血脂以及心电图的变化,并进行统计学分析。结果:治疗组和对照组改善心绞痛症状的有效率分别为94.64%和76.79%,治疗组有效率显著高于对照组,(P<0.05)。治疗后2组患者心电图均较治疗前明显改善(P<0.05),但治疗组与对照组治疗后比较无显著性差异。治疗后血脂指标明显改善,治疗组优于对照组(P<0.05)。结论:丹参川芎嗪注射液静脉滴注联合脑心通口服治疗冠心病心绞痛的疗效显著优于前者单独用药,具有临床推广价值。

Objective： To investigate the clinical efficacy of Salvia miltiorrhiza and ligustrazine injection combined NaoXintong through the treatment of angina pectoris heart. Methods： 112 Patients with angina pectoris, which were ran- domly divided into treatment group and control group using random number table, 56 cases for each group. The control group were treated with Salvia miltiorrhiza,and the treatment group was treated with Naoxintong treatment on this basis. 15 days for a course of the treatment. Angina symptoms, blood lipids and ECG changes were observed before and af- ter treatment, and the result were statistical analysis. Results： The effectiveness of the treatment group and the control group in improving the symptoms of angina were 94.64% and 76.79%, respectively, The effectiveness of treatment group was significantly higher（P〈0.05）. The two groups of patients after treatment significantly improved ECG than before treatment（P〈0.05）, but there were no significant difference between the treatment group and the control group. Lipids were significantly improved after treatment, the treatment group were better than the control group （P〈0.05）. Conclu-sion： Salvia miltiorrhiza and ligustrazine injection combined Naoxintong treatment of angina pectoris was significantly better than the former single drug and it＇ s worth of clinical promotion.